Genetic Analysis and Bio-Rad Laboratories have entered an agreement to further develop GA-map technology in routine healthcare.

According to the agreement, Bio-Rad will be responsible for the commercialisation of GA-map technology in some territories, to detect gut Dysbiosis.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Boehringer Ingelheim and China South East University Institute of Life Sciences have entered a research agreement to develop new treatments for hearing loss.

According to the agreement, the two partners will evaluate the key signalling pathways and proteins involved in the regeneration of the inner ear and develop a strategy for drug development.

The agreement enables the partners to regenerate hair cells from inner ear stem cells.

See Also:

Vigene Biosciences has entered a definitive agreement to acquire cGMP manufacturing facility and other assets from Omnia Biologics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Boehringer Ingelheim and China South East University Institute of Life Sciences have entered a research agreement to develop new treatments for hearing loss."

Shulman, Rogers, Gandal, Prody & Ecker PA is acting as legal advisor for the transaction.

The transaction will allow Vigene Biosciences to expand its gene and cell therapy product pipeline.

Laurus Labs Private plans to raise $198m through the initial public offering of its common stock shares.

Citigroup, Jefferies India Private, Kotak Securities and SBI Capital Markets are acting as lead book runners for the offering.

The company plans to use the proceeds for repaying its debts and for general corporate purposes.

Galera Therapeutics has raised $15m in a series B financing round led by Sofinnova Ventures.

The company plans to use proceeds to advance the phase III trials of GC4419 and also to develop its product pipeline for selective dismutase mimetics.